<i>In Vitro</i> Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with <i>FKS</i> Mutations

Abstract

Ibrexafungerp is a first-in-class glucan synthase inhibitor. <i>In vitro</i> activity was determined for 89 <i>Candida glabrata</i> isolates with molecularly identified <i>FKS1</i> or <i>FKS2</i> mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant <i>C. glabrata</i> isolates.